Bristol Myers Squibb’s GPRC5D-directed CAR-T therapy arlo-cel has met the key efficacy endpoints of the Phase 2 QUINTESSENTIAL trial in heavily pretreated multiple myeloma. The results could be particularly important for patients whose disease has progressed after BCMA-directed treatment.
OL-101, a novel BCMA/GPRC5D dual-target CAR-T cell therapy, achieved 100% ORR and deep responses in a Phase I study of heavily pretreated R/R multiple myeloma patients, including those with prior CAR-T exposure and extramedullary disease, presented at EHA 2026.
Multiple myeloma (MM), a malignant plasma cell disorder, continues to pose major treatment challenges for patients with relapsed or refractory disease (R/R MM), despite continuous advances in therapeutic options. While
A new study in the Journal of Clinical Oncology highlights MCARH109, a GPRC5D-targeted CAR-T cell therapy, showing promise for relapsed/refractory multiple myeloma patients after BCMA therapy failure.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.